Aardvark Therapeutics, Inc. Common Stock Total Liabilities
Aardvark Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Aardvark Therapeutics, Inc. Common Stock (AARD) has total liabilities worth $10.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AARD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aardvark Therapeutics, Inc. Common Stock (2022–2024)
Total liabilities of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Aardvark Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Aardvark Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cuhadaroglu Metal Sanayi ve Pazarlama AS
IS:CUSAN
|
Turkey | TL5.15 Billion |
|
Advance NanoTek Limited
F:BBJ
|
Germany | €3.36 Million |
|
MST GOLF GROUP BERHAD
KLSE:5316
|
Malaysia | RM125.56 Million |
|
PUC Bhd
KLSE:0007
|
Malaysia | RM53.85 Million |
|
CVD Equipment Corporation
NASDAQ:CVV
|
USA | $2.78 Million |
|
Samil Enterprise Co. Ltd
KQ:002290
|
Korea | ₩23.96 Billion |
|
Wysiwyg Studios Co. Ltd
KQ:299900
|
Korea | ₩113.00 Billion |
|
Capital Partners S.A.
WAR:CPA
|
Poland | zł89.65K |
Liability Composition Analysis (2022–2024)
This chart breaks down Aardvark Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AARD total asset value.
Liquidity & Leverage Metrics
Aardvark Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Aardvark Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aardvark Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual total liabilities of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $132.15 Million | +191.48% |
| 2023-12-31 | $45.34 Million | +1.47% |
| 2022-12-31 | $44.68 Million | -- |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more